Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

IMO, BP B-deal not likely at this time

If NIAID, as a result of their testing, deems brilacidin worthy, they will develop brilacidin through phase 2 for viral and/or fungal indications. Consider the following:

In which phase of clinical trials do the most pharmaceuticals fail?

Phase II clinical studies represent a critical point in determining drug costs, and phase II is a poor predictor of drug success: >30% of drugs entering phase II studies fail to progress, and >58% of drugs go on to fail in phase III.

https://www.google.com/search?q=at+what+stage+of+drug+clinical+trials+are+deals+usually+made+between+pharmaceutical+compaNIES&rlz=1C1CHBF_enUS979US979&ei=sMEZZLKcIraoqtsPyfqvwA8&ved=0ahUKEwiytOGdoO39AhU2lGoFHUn9C_gQ4dUDCBA&oq=at+what+stage+of+drug+clinical+trials+are+deals+usually+made+between+pharmaceutical+compaNIES&gs_lcp=Cgxnd3Mtd2l6LXNlcnAQDDoECAAQR0oECEEYAFDMEFjXdmDZuQFoAHACeACAAYkBiAGcBZIBAzUuMpgBAKABAcgBCMABAQ&sclient=gws-wiz-serp

Further consider the cost:

The average cost of phase 1, 2, and 3 clinical trials across therapeutic areas is around $4, 13, and 20 million respectively.

https://www.google.com/search?q=average+cost+of+a+fda+clinical+trial+phase+2+trial&rlz=1C1CHBF_enUS979US979&oq=average+cost+of+a+fda+clinical+trial+phase+2&aqs=chrome.1.69i57j33i160l3j33i299l2.35222j0j7&sourceid=chrome&ie=UTF-8

Why would any BP want to assume these risks and costs when they can possibly make a deal later, after the gov't has assumed these risks and costs? This is just basic business sense.

For the most part, NIAID is driving this "brilacidin train" and, COVID aside, they haven't conducted any clinical trials yet.

This is not a stock for the impatient.